Cite
MLA Citation
Farrukh T. Awan et al.. “A randomized, open‐label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia.” British journal of haematology, vol. 167, n.d., pp. 466–477. http://access.bl.uk/ark:/81055/vdc_100024973685.0x00005d